Alnylam Pharmaceuticals
ALNY
#619
Rank
โ‚น3.975 T
Marketcap
โ‚น29,777
Share price
3.68%
Change (1 day)
4.99%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

Alnylam Pharmaceuticals (ALNY) - Total debt

Total debt on the balance sheet as of March 2026 : โ‚น121.19 Billion

According to Alnylam Pharmaceuticals 's latest financial reports the company's total debt is โ‚น121.19 Billion. A companyโ€™s total debt is the sum of all current and non-current debts.

Alnylam Pharmaceuticals - Total debt on balance sheet (from 2003 to 2026)

Total debt by year

Year Total debt Change
2025-12-31โ‚น114.76 B3.22%
2024-12-31โ‚น111.18 B2.31%
2023-12-31โ‚น108.67 B-0.53%
2022-12-31โ‚น109.25 B47.13%
2021-12-31โ‚น74.25 B94.8%
2020-12-31โ‚น38.11 B75.93%
2019-12-31โ‚น21.66 B932.85%
2018-12-31โ‚น2.09 B9.51%
2017-12-31โ‚น1.91 B-81.21%
2016-12-31โ‚น10.19 B
2007-12-31โ‚น0.26 B-34.45%
2006-12-31โ‚น0.40 B21.59%
2005-12-31โ‚น0.33 B6.71%
2004-12-31โ‚น0.31 B268.45%
2003-12-31โ‚น84.64 M

Total debt for similar companies or competitors

Company Total debt/th> differencediff. Country
Novartis
NVS
โ‚น4.474 T 3,591.73%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
Sanofi
SNY
โ‚น2.206 T 1,720.24%๐Ÿ‡ซ๐Ÿ‡ท France
Regeneron Pharmaceuticals
REGN
โ‚น257.63 B 112.57%๐Ÿ‡บ๐Ÿ‡ธ USA
Sarepta Therapeutics
SRPT
โ‚น98.69 B-18.57%๐Ÿ‡บ๐Ÿ‡ธ USA
Regulus Therapeutics
RGLS
โ‚น0.13 B-99.89%๐Ÿ‡บ๐Ÿ‡ธ USA
OPKO Health
OPK
โ‚น37.77 B-68.83%๐Ÿ‡บ๐Ÿ‡ธ USA
Teva Pharmaceutical Industries
TEVA
โ‚น1.609 T 1,228.06%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel
Arrowhead Pharmaceuticals
ARWR
โ‚น94.19 B-22.28%๐Ÿ‡บ๐Ÿ‡ธ USA